OPKO Health (NASDAQ:OPK) Cut to “Sell” at StockNews.com

StockNews.com downgraded shares of OPKO Health (NASDAQ:OPK) from a hold rating to a sell rating in a research note issued to investors on Thursday.

Several other analysts also recently weighed in on OPK. Barrington Research restated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Friday, November 8th. Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a research report on Tuesday, September 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research note on Thursday, September 26th.

OPKO Health Stock Down 2.6 %

OPKO Health stock opened at $1.48 on Thursday. The firm has a market capitalization of $1.01 billion, a P/E ratio of -7.79 and a beta of 1.62. The stock’s fifty day simple moving average is $1.55 and its 200-day simple moving average is $1.48. OPKO Health has a twelve month low of $0.85 and a twelve month high of $1.76. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

Insider Buying and Selling at OPKO Health

In other news, CEO Phillip Md Et Al Frost acquired 100,000 shares of OPKO Health stock in a transaction dated Thursday, November 14th. The shares were acquired at an average cost of $1.62 per share, with a total value of $162,000.00. Following the purchase, the chief executive officer now directly owns 211,612,405 shares of the company’s stock, valued at approximately $342,812,096.10. This trade represents a 0.05 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders acquired 1,304,255 shares of company stock worth $2,024,605 in the last 90 days. 47.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On OPKO Health

Several hedge funds have recently modified their holdings of OPK. Rubric Capital Management LP lifted its stake in shares of OPKO Health by 9.6% in the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after acquiring an additional 4,284,336 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of OPKO Health by 142.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after acquiring an additional 876,272 shares during the period. Squarepoint Ops LLC bought a new position in OPKO Health in the 2nd quarter worth about $592,000. Y.D. More Investments Ltd bought a new position in OPKO Health in the 2nd quarter worth approximately $1,840,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of OPKO Health by 736.7% during the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 217,450 shares during the period. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.